Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2409021 After Escalating Single Oral Dose Administration in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.

Next Previous
Trial Profile

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2409021 After Escalating Single Oral Dose Administration in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adomeglivant (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 27 May 2012 Additional location (Singapore), actual initiation date (May 2007) added and official title amended as reported by ClinicalTrials.gov.
  • 27 May 2012 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
  • 27 May 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01606371).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top